Based on the evidence, CAR T-cells manufactured with Interleukin-15 are predicted to exhibit a significantly more robust, polyfunctional, and sustained release of key effector cytokines (such as IFN-γ and TNF-α) upon antigen stimulation compared to CAR T-cells manufactured without IL-15.